Selected Start-Ups (06/00)
In Vivo summarizes the technologies of several recently founded companies: BioProtocol Inc.'s web site, Bioprotocol.com, will offer life scientists free access to high quality protocols to guide their research. Locus Discovery Inc. has a computational approach for designing small molecule therapeutics that can act as inhibitors or activators of protein activity. Morphotek Inc. is developing an in vivo technology that can alter the genome of microbe, plant, and mammal host cells to produce organisms with commercially viable output traits. NitroOSystems Inc. hopes that its tolerance-free nitrate therapy will become the standard of care for the treatment of angina, congestive heart failure, hypertension, and other cardiovascular disorders. Repair Inc. is developing therapeutics for cardiovascular disease based on its proprietary drug delivery and angiogenesis technologies. Unipharm Technologies Limited claims that its approach to drug delivery will render existing quick dissolve oral dosage forms unnecessary and aid drugs that have negative esophgeal or gastric mucosal effects.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."